Clinical Trial Update: A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease. [Phase 4]

View source ↗

Summary

A Phase 4 multicenter trial evaluating the efficacy of Cerezyme for skeletal disease in Gaucher disease type I has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease Type

Drugs mentioned

• CEREZYME (imiglucerase)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Gaucher Disease Type I, Cerebroside Lipidosis Syndrome | Phase 4 | Status: COMPLETED